A judge has lashed the “unsatisfactory” lack of cooperation between British automotive distributor Inchcape and Chubb in a $2.3 million dispute over coverage for a cyber attack which caused over $4 million in loss.
Engineering services firm CIMIC Group has launched proceedings against ten insurers seeking indemnity for costs arising from allegations the company engaged in corrupt practices, including bribing government officials in Iraq.
A Western Australia Supreme Court judge has dodged a lawsuit by a kosher compliance inspector who alleged he was defamed by an email that claimed the inspector did not have “shem tov”, or a good name, in Perth’s Jewish community.
Pharmaceutical companies Sanofi and Bristol-Myers Squibb are liable for losses to the federal government for excess subsidies it allegedly paid for the blood-thinner Plavix after an unjustified court injunction prevented the release of a generic version of the top-selling drug, an appeals court has heard.
An upcoming class action trial over alleged side effects resulting from the Hendra virus horse vaccine, which will commence shortly after a COVID-19 vaccine is rolled out in Australia, will raise “timely” issues concerning vaccine safety, a judge has heard.
Fifty horse owners may face cross-examination regarding adverse effects allegedly caused by Zoetis’ Hendra virus vaccine, with the company warning a four-week hearing scheduled to begin in March may be insufficient to deal with the horse owners’ evidence.
Global animal health company Zoetis has told the lead applicants in a class action over horse vaccines to “put up or shut up” and produce evidence disclosing an alleged scientific link between the hendra virus vaccine and certain alleged adverse side effects.
A court has dismissed a claim by the Australian Government for $325 million against pharmaceutical companies Sanofi and Bristol-Myers Squibb allegedly owed for excess subsidies it paid for blood-thinner Plavix as a result of an interlocutory injunction blocking a generic version of the blockbuster drug.
Noting the relevant three-year limitations provision was “quite unusal”, the judge overseeing a consumer class action against horse vaccine manufacturer Zoetis has given the class a chance to add a second applicant to the case, after it was revealed that part of the lead applicant’s claim was out of time.